FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)																
Name and Address of Reporting Person * Rouhandeh Steven H				2. Issuer Name and Ticker or Trading Symbol PLASMATECH BIOPHARMACEUTICALS INC [PTBI]							LS IN	IC _	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director					
(Last) (First) (Middle) PLASMATECH BIOPHARMACEUTICALS, INC., 1325 AVENUE OF THE AMERICAS 27TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 05/11/2015											Execu	ttive Chairm	an	
(Street) NEW YORK, NY 10019				4. If Amendment, Date Original Filed(Month/Day/Year))		6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							rities	Acquire	red, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year	2A. Deem Execution any (Month/De		Date, if	(Instr. 8)			4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)			f (D) C	5. Amount of Securities I Owned Following Report Transaction(s) (Instr. 3 and 4)		d	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership
			(iviona	Du	y, rear)	Coe	de	V	Ar	nount	(A) or (D)	Price	mou. 5 und	,		or Indirect (I) (Instr. 4)		
Common stock		05/11/2015	15			A			375 (1)	5,000 (2)	A	\$ 7.34 3	375,000		D			
Reminder:	Report on a	separate line for eac	h class of securities Table II -	Derivati	ive S	ecuritie	s Acq	uire	Person in this displa ed, Disp	ns v for ys a	rm are r a curre d of, or l	not rently v Benef	equired valid ON icially C	to respon IB contro	of informa d unless the number.		ned SEC	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction I Code (Instr. 8)		5. Number of		6. Date Expiration (Month/D				7. Title and Amoun of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s	Owners Form o Derivat Securit Direct (or Indir	Ownership (Instr. 4)	
				Code	V	(A)	(D)	Da Ex	ate ercisabl	e	Expiration Date	on	Title	Amoun or Number of Share		(Instr. 4)	(Instr. 4)
Stock option (right to buy)	\$ 7.34	05/11/2015		A		125,00 (2)	0	05	5/11/20	16	05/11/2	2025	Comm	1125.00	0 \$ 7.34	205,000	D	

Reporting Owners

Relationships						
Director	10% Owner	Officer	Other			
X	X	Executive Chairman				
		Director 10% Owner	Director 10% Owner Officer			

Signatures

/s/ Steven H. Rouhandeh	05/13/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 375,000 shares of restricted common stock will vest on 05/11/2019.
- (2) 100% accelerated vesting on change of control.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \textit{see}\ Instruction\ 6 for procedure.$

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.